Eidos Therapeutics, a clinical stage biopharmaceutical company, is generating buzz in the industry as it aims to address the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). With its focus on developing acoramidis, a potentially disease-modifying therapy for the treatment of ATTR, Eidos Therapeutics is poised to make a splash in the growing biotech space.